Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-07-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerstagecarcinomacellsbowel
  Phrases that lowered it: jointaminotransferasecarboplatinviruslaboratory
• Sponsor's past termination rate: 28.1% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 154 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 7237 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 22.8% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 41868 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 526 (lowers risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ganetespib Window of Opportunity Study in Head and Neck Cancers NCT02334319 · started 2014 · scored riskier than 99% of active trials terminated
• Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT01962948 · started 2013 · scored riskier than 80% of active trials terminated
• European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer NCT03783949 · started 2018 · scored riskier than 81% of active trials completed
• A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma NCT01485835 · started 2012 · scored riskier than 94% of active trials completed
• Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer NCT01554969 · started 2012 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.